Insiders Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 08:50:00 13/05/2026 pm IST			5-day change	1st Jan Change
299.20 ^DKK	+0.91%		+3.07%	-8.01%

15/05	European Equities Traded in the US as American Depositary Receipts Down Sharply in Friday Trading	MT
15/05	Sandoz Lands EU Nod for Insulin Biosimilars Bysumlog, Dazparda	MT

Insiders

27/03	Novo Nordisk AS Announces Board Appointments	CI
27/03	Novo Nordisk A/S Approves Board Changes	CI
02/03	Novo Nordisk A/S Announces Changes of Employee Representatives to the Board of Directors	CI
23/02	Novo Nordisk's CEO says still 'incredibly optimistic' about CagriSema	RE
23/02	Novo Nordisk's CEO: We need to be aware that there is an abnormality with how the comparator drug has performed in the study	RE
23/02	Novo Nordisk's CEO: I am still incredibly optimistic about Cagrisema	RE
23/02	Novo Nordisk's CEO: We strongly believe that Cagrisema has right now the best weight efficacy than any product currently on the market	RE
23/02	Novo Nordisk's chief scientific officer: assuming that there is further weight loss potential to be had with Cagrisema	RE
20/02	Novo Nordisk board proposes re-election of Lars Rebien Sorensen as chair	RE
20/02	Novo Nordisk nominates two drug industry veterans to strengthen board	RE
10/02	Novo Says It's Suing Hims to Halt Obesity Drug Copycats	MT
09/02	Hims & Hers Stops Selling Wegovy Copycat Weight-Loss Pill	MT
09/02	PRESS DIGEST- New York Times business news - Feb 9	RE
04/02	Novo Nordisk plunges as its 2026 outlook rattles investors
04/02	Novo Nordisk CEO: The big uptake of the Wegovy pill more than justifies the reduced price	RE
04/02	Novo Nordisk CEO: We don't see our Wegovy pill price strategy as a gamble; we think it's our responsibility to be able to give all the people in need the medications that we are making	RE
04/02	Novo Nordisk CFO: Our price point in the U.S. for Wegovy is very close to compounders' price points	RE
04/02	Novo Nordisk CFO: We are looking at a percentage decline in 2026 U.S. sales in the "teens"	RE
04/02	Novo Nordisk CFO: 'Most-Favored Nation' Is a Meaningful Driver of Lower Prices in the U.S.; But the Bigger Driver Is Related to a Bigger Cash Business	RE
04/02	Novo Nordisk CFO: Our semeglutide patent in India expires in a few months; we expect more generic competition in India on the obesity drug market	RE
04/02	Novo Nordisk CFO tells Reuters: still very low penetration on the Chinese obesity drug market; competition there has been intense	RE
04/02	Novo Nordisk sees 'painful' US price cuts for Wegovy as investment in the future	RE
04/02	Novo Nordisk CEO: We have no plans for systematic mass layoffs this year	RE
04/02	Novo Nordisk CEO: We expect to introduce new strategic aspirations as part of our Capital Markets Day	RE
04/02	Novo Nordisk Q4 media conference call ends	RE